9,601 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by AG2R LA Mondiale Gestion D Actifs

Key Points

• AG2R LA Mondiale Gestion D Actifs acquired 9,601 shares of Vertex Pharmaceuticals, valued at approximately $4.24 million, during the first quarter of the year.
• In related insider activity, Director Bruce I. Sachs purchased 5,000 shares at an average price of $389.68, increasing his ownership by 12.50%.
• Vertex Pharmaceuticals recently reported a quarterly earnings per share (EPS) of $4.52, beating estimates, with a net revenue of $2.94 billion, a year-over-year increase of 11.3%.

AG2R LA Mondiale Gestion D Actifs bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,601 shares of the pharmaceutical company's stock, valued at approximately $4,244,000.

Other institutional investors have also added to or reduced their stakes in the company. Activest Wealth Management purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd increased its position in Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 45 shares during the period. Mascagni Wealth Management Inc. purchased a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $31,000. Flaharty Asset Management LLC purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $32,000. Finally, Mpwm Advisory Solutions LLC purchased a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $40,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Insider Activity

In related news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares of the company's stock, valued at $17,535,600. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Up 2.3%

VRTX stock opened at $397.37 on Friday. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.88. The firm has a 50 day moving average of $423.87 and a 200 day moving average of $454.15. The stock has a market capitalization of $101.88 billion, a PE ratio of 28.40 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. During the same period in the previous year, the business posted ($12.83) EPS. The business's quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of analyst reports. UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a "buy" rating in a research report on Tuesday, August 5th. BMO Capital Markets set a $530.00 price target on Vertex Pharmaceuticals and gave the stock an "outperform" rating in a research note on Tuesday, August 5th. Guggenheim cut their price objective on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Friday, August 22nd. Finally, Truist Financial set a $490.00 target price on shares of Vertex Pharmaceuticals and gave the stock a "buy" rating in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $496.05.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.